Granato Mariana F, Ferraro Alexandre A, Lellis Denise M, Casella Erasmo B
Pediatrics Department, School of Medicine, University of Sao Paulo, Av. Dr. Enéas Carvalho de Aguiar, 647, 05403.000, São Paulo, SP, Brazil.
Behav Neurol. 2018 Oct 2;2018:7341529. doi: 10.1155/2018/7341529. eCollection 2018.
Attention-deficit hyperactivity disorder (ADHD) has been found to co-occur frequently with obesity, although the reasons for this association are unknown. The aim of this study was to compare the nutritional profile of a Brazilian cohort of ADHD patients with that of the general population and to analyze the association between ADHD drug treatment (with methylphenidate), nutritional status, and height of these individuals. In the first phase of the study, we designed the nutritional and height profile of 93 ADHD patients (5.1 to 13.8 years old) and compared it to a control group. In the second phase, we analyzed the association of the use of methylphenidate with nutritional status and height. The results showed that the prevalence of overweight/obesity was statistically higher in the cohort of ADHD patients compared to controls (40.9% vs. 34.7%; < 0.05). After treating ADHD patients with methylphenidate, a statistically significant decrease in the BMI -score was observed (0.695 vs. 0.305; < 0.01). On the other hand, no significant impact on height was detected after treatment (0.189 vs. 0.248; = 0.298). In conclusion, the results suggest that the use of methylphenidate in patients who have ADHD and obesity is relevant not only for controlling ADHD symptoms but also for improving the nutritional status of these individuals. Moreover, the treatment did not affect the patients' height.
注意缺陷多动障碍(ADHD)已被发现常与肥胖同时出现,尽管这种关联的原因尚不清楚。本研究的目的是比较巴西一组ADHD患者与普通人群的营养状况,并分析ADHD药物治疗(使用哌甲酯)、营养状况和这些个体身高之间的关联。在研究的第一阶段,我们设计了93名ADHD患者(5.1至13.8岁)的营养和身高状况,并将其与对照组进行比较。在第二阶段,我们分析了哌甲酯的使用与营养状况和身高之间的关联。结果显示,与对照组相比,ADHD患者队列中超重/肥胖的患病率在统计学上更高(40.9%对34.7%;<0.05)。用哌甲酯治疗ADHD患者后,观察到BMI评分有统计学意义的下降(0.695对0.305;<0.01)。另一方面,治疗后未检测到对身高有显著影响(0.189对0.248;=0.298)。总之,结果表明,在患有ADHD和肥胖症的患者中使用哌甲酯不仅与控制ADHD症状有关,而且与改善这些个体的营养状况有关。此外,治疗并未影响患者的身高。